• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Warner-Chilcott Plc: PharmaVitae Profile Product Image

Warner-Chilcott Plc: PharmaVitae Profile

  • Published: December 2010
  • Region: Global
  • 69 pages
  • Datamonitor

Introduction

This analysis examines the historical and forecast performance for Warner Chilcott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

- Gain insight into Warner Chilcott's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

- Strategic insight into the prospects for Warner Chilcott over the next six years.
- Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

- Benchmark Warner Chilcott's performance against key rivals in the prescription pharmaceutical sector
- Assess the commercial and strategic implications of the Proctor & Gamble acquisition in 2009
- Analyze how Warner Chilcott will prepare for patent expiry across its newly acquired flagship brands prior to 2015

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–
Financial performance, 2003–
Warner Chilcott: PharmaVitae forecasts at a glance
Strategic insight
[Missing title]
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest quarterly sales
Latest prescription pharma product news
Q4
Q3
Q2
Q1
Q4
COMPANY INTRODUCTION
Background
M&A history
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–
Product analysis
Product analysis, 2009–
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-
Core analysis, 2009-
Expiry analysis, 2009-
Launch/core/expiry configuration, 2009–
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–
Operating costs and profit analysis
Operating costs and profit analysis, 2003–
Operating cost ratio and profit margin analysis, 2003–
Operating cost ratio and profit margin analysis, 2009–
Operating costs and profit analysis, 2009–
KEY PRODUCTS
Overview
Asacol
Actonel
Enablex
Loestrin
Estrace
Doryx
APPENDIX
Abbreviations
Exchange rates

Note: Product cover images may vary from those shown

RELATED PRODUCTS